Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma

[1]  K. Hekmat,et al.  Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy , 2021, npj Precision Oncology.

[2]  P. Sharma,et al.  The Next Decade of Immune Checkpoint Therapy. , 2021, Cancer discovery.

[3]  Zihua Zeng,et al.  T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Van Loo,et al.  Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition , 2021, Cell.

[5]  J. Adam,et al.  Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. , 2020, Clinical lymphoma, myeloma & leukemia.

[6]  C. Bollard,et al.  Increased Tumor Specific Cytotoxic T Cell Responses and Reversion to a Favorable Cytokine Profile after Treatment in Patients with Newly Diagnosed High Risk Hodgkin Lymphoma Treated on Children's Oncology Group Trial-AHOD1331 , 2020 .

[7]  A. Rosenwald,et al.  Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial , 2020 .

[8]  M. Dietlein,et al.  Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial , 2020, Clinical Cancer Research.

[9]  K. Kelly,et al.  LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma , 2020, Leukemia & lymphoma.

[10]  A. Rosenwald,et al.  Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. , 2020, Blood.

[11]  W. Hwang,et al.  Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma , 2020, Journal for ImmunoTherapy of Cancer.

[12]  R. Advani,et al.  Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma. , 2020, Blood.

[13]  M. Hino,et al.  The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. , 2020, Blood advances.

[14]  D. Neuberg,et al.  A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma , 2020, Nature Medicine.

[15]  A. van den Berg,et al.  Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58. , 2020, Blood.

[16]  A. Rosenwald,et al.  Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. , 2020, JAMA oncology.

[17]  Allen W. Zhang,et al.  Single cell transcriptome analysis reveals disease-defining T cell subsets in the tumor microenvironment of classic Hodgkin lymphoma. , 2019, Cancer discovery.

[18]  Andrew J. Dunford,et al.  Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. , 2019, Blood advances.

[19]  M. Shipp,et al.  The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative. , 2019, Blood.

[20]  R. Elstrom,et al.  Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study , 2019, Leukemia.

[21]  K. Savage,et al.  Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Brock,et al.  Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Ascierto,et al.  CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Dai,et al.  Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer , 2018, Front. Immunol..

[25]  Ludmila V. Danilova,et al.  The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity , 2018, Cancer Immunology Research.

[26]  Aviv Regev,et al.  Induction and transcriptional regulation of the co-inhibitory gene module in T cells , 2018, Nature.

[27]  K. Savage,et al.  Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  K. Savage,et al.  Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Mark S. Anderson,et al.  Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. , 2017, JCI insight.

[30]  David M. Woods,et al.  Predictors of responses to immune checkpoint blockade in advanced melanoma , 2017, Nature Communications.

[31]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[32]  M. Shipp,et al.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Yokota,et al.  Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition , 2017, Clinical Cancer Research.

[34]  A. van den Berg,et al.  HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy? , 2017, Oncoimmunology.

[35]  S. Robson,et al.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets , 2017, Immunological reviews.

[36]  M. Shipp,et al.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Y. Natkunam,et al.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Aviv Regev,et al.  A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells , 2016, Cell.

[39]  A. Younes,et al.  The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints , 2016, Haematologica.

[40]  Ana C Anderson,et al.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.

[41]  J. Wolchok,et al.  Targeting T Cell Co-receptors for Cancer Therapy. , 2016, Immunity.

[42]  K. Tanriverdi,et al.  PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma , 2015, Acta Haematologica.

[43]  O. Elemento,et al.  Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. , 2015, Blood.

[44]  R. Blasczyk,et al.  Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches. , 2014, Journal of immunological methods.

[45]  R. Spang,et al.  Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. , 2013, Blood.

[46]  S. Gnjatic,et al.  Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin’s lymphoma patients , 2012, Cancer Immunology, Immunotherapy.

[47]  Michael R. Green,et al.  Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy , 2012, Clinical Cancer Research.

[48]  U. Gerdemann,et al.  Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  Ralf Küppers,et al.  The biology of Hodgkin's lymphoma , 2009, Nature Reviews Cancer.

[50]  R. Yamamoto,et al.  PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. , 2007, Blood.

[51]  T. Zander,et al.  RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma. , 2007, Blood.